QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Pioneers Non-Controversial Stem Cell Technology 0 comments
    Oct 4, 2013 10:32 AM | about stocks: ISCO

    Biotechnology company International Stem Cell Corp. is focused on using parthenogenesis, its powerful stem cell technology, to treat diseases of the eye, nervous system, and liver - diseases for which cell therapy has been clinically proven but is hampered by the lack of safe immune-matched human cells or tissue.

    Parthenogenesis uses unfertilized human eggs (oocytes) to create parthenogenetic stem cells (hpSC) that can be immune-matched to millions of people. From a relatively small number of hpSC lines, sufficient immune-matched cells could be provided to accommodate a large portion of the human population. Using unfertilized oocytes offers an ethical advantage over other types of stem cells, and the advantage of immunomatching makes parthenogenetic stem cells a highly favorable source for cell-based therapy.

    In parthenogenesis, stem cells are created by chemically stimulating oocytes to begin division. The eggs are not fertilized; therefore no viable embryo is created or destroyed - avoiding the leading contention against stem cell research. Different activation techniques can be applied to human oocytes to allow either the creation of human leukocyte antigen (HLA) heterozygous hpSC lines, which are HLA-matched/histocompatible with just the donor of the oocyte, or HLA homozygous hpSC, which can be histocompatible with a vast number of people. Because the cells inherit a duplicate set of HLA genes, the possibility of the derived cells being rejected by the immune system is significantly reduced, making a single cell suitable to treat millions of individuals.

    By addressing this problem of immune-rejection, parthenogenesis has the potential to significantly advance the field of regenerative medicine.

    For more information, visit the ISCO website at internationalstemcell.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.